Elutia (NASDAQ:ELUT) Stock Breaks Above 50 Day Moving Average – Here’s Why

Elutia Inc. (NASDAQ:ELUT – Get Free Report) shares passed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $0.82 and traded as high as $0.9199. Elutia shares last traded at $0.9040, with a volume of 83,580 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Elutia from a “sell (d)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the company presently has a consensus rating of “Sell”.

Get Our Latest Analysis on ELUT

Elutia Trading Up 11.6%

The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.61 and a current ratio of 2.63. The stock has a market capitalization of $40.14 million, a PE ratio of 0.81 and a beta of 0.93. The stock has a 50-day moving average price of $0.82 and a two-hundred day moving average price of $0.96.

Elutia (NASDAQ:ELUT – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.11. Elutia had a net margin of 546.70% and a negative return on equity of 140.53%. The company had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.00 million.

About Elutia

(Get Free Report)

Elutia is a medical technology company focused on developing biologic products for use in surgery. Its portfolio includes envelopes designed to support cardiac implantable electronic devices, such as pacemakers and defibrillators. The company’s products include CanGaroo, an extracellular-matrix envelope designed to help secure and support implanted devices, and EluPro, an antibiotic-eluting envelope intended to help reduce the risk of infection associated with these devices. Elutia was formerly known as Aziyo Biologics and adopted its current name in 2023 as it focused its business on drug-eluting biologic technologies.

Further Reading

Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.